Dr Lambertini speaks at a SABCS 2017 press session about a meta-analysis of individual patient data from five randomised clinical trials provided a high level of evidence that treatment with a gonadotropin-releasing hormone analog (GnRHa) could safely and effectively protect ovarian function, and potentially preserve fertility in premenopausal women receiving chemotherapy for early-stage breast cancer.

Read the news story for more.